Trius to Present at Credit Suisse Healthcare Conference

SAN DIEGO, Nov. 7, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Friday, November 11 at 7:30 a.m. at the 20th Annual Credit Suisse Healthcare Conference. The presentation will take place at the Arizona Biltmore Hotel.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. The company's lead investigational drug, tedizolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of ABSSSI. Trius has two Special Protocol Assessments (SPA) with the FDA for its two Phase 3 ABSSSI trials and has partnered with Bayer HealthCare for the development and commercialization of tedizolid phosphate outside of the U.S. and the European Union. In addition to the company's tedizolid phosphate clinical program, Trius is currently conducting three preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit www.triusrx.com.

CONTACT: Public Relations Contact:
         Jason Spark at Canale Communications, Inc.
         [email protected]
         619-849-6005

         Investor Relations Contact:
         Stefan Loren at Westwicke Partners, LLC
         [email protected]
         443-213-0507